Chronic graft versus host disease
MONDO:0020547Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown.It likely results from a complex immune-mediated interaction between the donor and recipient cells.Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.
Also known as: GVHD, chronic, graft versus host disease, chronic, chronic GVHD
115 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug hope for stem cell transplant complication
Disease control Recruiting nowThis study tests a drug called pacritinib in people with moderate or severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. cGVHD is an immune disorder that can damage organs and cause disability. Participants must be 18 or older and have not responded to …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 23:00 UTC
-
New combo therapy aims to tame chronic GVHD
Disease control Recruiting nowThis study tests whether adding axatilimab to standard steroid treatment helps people with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. About 240 participants aged 12 and older will receive either axatilimab or a placebo…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to tame chronic GVHD
Disease control Recruiting nowThis study tests whether combining a drug called axatilimab with a blood-filtering procedure (ECP) can help people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. About 49 participants who have tried at least two prior treatments will …
Phase: PHASE2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for GVHD patients who failed other treatments
Disease control Recruiting nowThis study tests a drug called axatilimab in people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants must have tried at least two other treatments without success. The goal is to …
Phase: PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for lung scarring after transplant: belumosudil trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug belumosudil can help people who develop bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a stem cell transplant. The study will enroll 45 participants with new or early-stage BOS. Participants will take belumosudil …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
JAKAVI under the microscope: new study tracks GVHD treatment in real life
Disease control Recruiting nowThis study is tracking the safety and effectiveness of the drug JAKAVI (ruxolitinib) in 395 patients with graft-versus-host disease (GVHD), a complication of bone marrow transplants. Researchers are monitoring infections and other side effects in patients receiving the drug in ro…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for stem cell transplant patients with severe immune complication
Disease control Recruiting nowThis study tests a drug called ruxolitinib in Chinese patients aged 12 and older who have chronic graft-versus-host disease (cGvHD) that did not improve with steroids. cGvHD is a condition where donor immune cells attack the patient's body after a stem cell transplant. The goal i…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug may help stem cell transplant patients avoid extra immune suppression
Disease control Recruiting nowThis study tests whether the drug belumosudil can prevent chronic graft-versus-host disease (cGVHD) from worsening in stem cell transplant recipients. About 82 participants will receive either belumosudil or a placebo. The goal is to see if the drug delays the need for additional…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for kids with transplant complication: belumosudil trial launches
Disease control Recruiting nowThis study tests the drug belumosudil in children aged 1 to 18 who have moderate-to-severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and whose condition has not improved with at least two prior treatments. The trial has two phases: the first finds th…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Blood cancer drug ibrutinib gets Long-Term safety check in 700-Patient study
Disease control Recruiting nowThis study offers continued access to the drug ibrutinib for up to 700 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) who are already taking it and benefiting. Researchers will track side effects and how the disease changes over time. Th…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for kids with chronic Graft-Versus-Host disease: axatilimab trial launches
Disease control Recruiting nowThis study tests a drug called axatilimab against the best available treatments for children aged 2 to 18 with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The trial enrolls 60 participants who have already tried at least two other treat…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New bone marrow transplant trial offers hope for kids with severe blood disorders
Disease control Recruiting nowThis study tests a bone marrow transplant from a family donor for children under 21 with severe non-cancer blood disorders like sickle cell disease, bone marrow failure, or immune problems. The goal is to see if the transplant can replace the diseased cells with healthy donor cel…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Herbal extract shows promise for stiff skin and joints in transplant survivors
Disease control Recruiting nowThis study tests whether adding madecassoside tablets (from the Centella asiatica plant) to standard treatment can help people with a severe form of chronic graft-versus-host disease that causes skin hardening and joint stiffness. About 30 participants aged 14 to 65 will take the…
Phase: PHASE2 • Sponsor: WeiShi • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Arthritis drug repurposed to fight stem cell transplant complication
Disease control Recruiting nowThis phase 3 trial tests whether iguratimod, a drug already used for rheumatoid arthritis, can safely and effectively treat chronic graft-versus-host disease (cGVHD) in people who have had a stem cell transplant. The study will enroll 20 adults who have persistent cGVHD despite p…
Phase: PHASE3 • Sponsor: Xuzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo aims to tame transplant complication without long-term steroids
Disease control Recruiting nowThis study tests a combination of two drugs, belumosudil and rituximab, as the first treatment for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The goal is to see if this approach can control the disease and reduce the need f…
Phase: PHASE2 • Sponsor: Northside Hospital, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Experimental cell injection targets stubborn GVHD
Disease control Recruiting nowThis early-phase trial tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The study will enroll 36 participants to check safety and see if the treatment can reduce symptoms. It's a first s…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for GVHD patients: ruxolitinib tested as First-Line therapy
Disease control Recruiting nowThis study compares two drugs, ruxolitinib and prednisone, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication after bone marrow transplant. About 120 adults who need systemic therapy for cGVHD will be randomly assigned to receive one of the two d…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibody drug targets skin scarring in transplant survivors
Disease control Recruiting nowThis study tests a drug called axatilimab for people whose skin becomes thick and hard (sclerotic) after a donor stem cell transplant, a condition called chronic graft-versus-host disease. The drug aims to block immune signals that cause inflammation and scarring. About 50 adults…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Crushed or whole? tiny study tests Pill-Swallowing workaround for cGVHD drug
Disease control Recruiting nowThis study is testing whether crushing belumosudil tablets and mixing them with water changes how the drug is absorbed in people with chronic graft-versus-host disease (cGVHD). Only 8 participants who have had a stem cell transplant will take the drug both ways and have their blo…
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug axatilimab tested for Hard-to-Treat Graft-Versus-Host disease in china
Disease control Recruiting nowThis study tests a drug called axatilimab in 30 Chinese patients with chronic graft-versus-host disease (cGVHD) that has come back or not improved after standard treatment. cGVHD is a complication of bone marrow or stem cell transplants where donor cells attack the patient's body…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo aims to tame Hard-to-Treat transplant complication
Disease control Recruiting nowThis early-stage trial tests whether adding fostamatinib to the standard drug ruxolitinib can safely help people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a serious complication after a stem cell transplant where the donor cells at…
Phase: PHASE1 • Sponsor: Stefanie Sarantopoulos, MD, PhD. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill aimed at Hard-to-Treat GVHD enters early human testing
Disease control Recruiting nowThis early-phase trial tests an oral drug called Q702 in 18 people with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of effectiveness. All participants have mo…
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug vimseltinib aims to tame chronic GVHD in failed treatments
Disease control Recruiting nowThis study tests whether the drug vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD) who have not improved after at least two prior treatments. About 48 participants will take vimseltinib daily for up to two years. The g…
Phase: PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for transplant patients with severe chronic GVHD
Disease control Recruiting nowThis study tests a new drug, rovadicitinib, for people with moderate to severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. Participants must have tried at least two prior treatments. The goal is to see if rovadicitinib improves symptoms better than sta…
Phase: PHASE3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowThis study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Desperate patients get early access to promising drug
Disease control AVAILABLEThis program provides early access to the drug ruxolitinib for people with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease. It is for patients who have no other treatment options and cannot join a clinical trial. Th…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New cell prep method aims to tame transplant complications in kids
Disease control AVAILABLEThis study offers a special way to prepare donor stem cells for children and teens under 22 who need a transplant but lack a perfectly matched sibling donor. The method uses the CliniMACS® system to remove certain immune cells, which may help reduce the risk of graft-versus-host …
Sponsor: Victor Aquino • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for chronic dry eye from Graft-Versus-Host disease: expanded access to d-MAPPS eye drops
Disease control AVAILABLEThis expanded access program makes an investigational eye drop called d-MAPPS available to adults with chronic ocular graft-versus-host disease (oGVHD), a painful dry eye condition that can occur after a stem cell or bone marrow transplant. The treatment is a protein-based soluti…
Sponsor: Regenerative Ocular Immunobiologics LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug axatilimab made available for one patient with chronic GVHD
Disease control AVAILABLEThis program offers expanded access to the drug axatilimab for a single patient with chronic graft versus host disease (GVHD), a complication after a stem cell transplant. The patient receives intravenous doses every two weeks. Approval is needed from the company, an ethics commi…
Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug cocktail aims to stop deadly transplant complication
Disease control Recruiting nowThis phase 2 trial tests whether a new way of giving anti-thymocyte globulin (ATG) along with standard drugs tacrolimus and methotrexate can prevent acute graft-versus-host disease (GVHD) after a stem cell transplant. The study enrolls 29 adults aged 18-60 with blood cancers who …
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New cell therapy aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis early-phase trial tests whether infusing specially prepared donor immune cells (Treg cells) along with low-dose interleukin-2 can safely treat refractory chronic graft-versus-host disease (cGVHD), a serious complication after stem cell transplants. The study will enroll 18 a…
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Dental cleaning may ward off deadly transplant complication
Prevention Recruiting nowThis study tests whether a dental cleaning shortly after a stem cell transplant can prevent chronic graft-versus-host disease (GVHD), a common and serious complication. Researchers will enroll 45 adults receiving a donor stem cell transplant for blood cancer. The goal is to see i…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
New hope for stem cell patients: drug may stop debilitating chronic GVHD
Prevention Recruiting nowThis early-stage trial tests whether the drug ruxolitinib can prevent chronic graft-versus-host disease (cGVHD) in 42 adults who had a stem cell transplant for blood cancer. Doctors use a blood test to find patients at high risk for cGVHD and then give them ruxolitinib to block t…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Light therapy tested for painful mouth sores after stem cell transplant
Symptom relief Recruiting nowThis phase 2 trial tests whether photobiomodulation (PBM) — a type of light therapy — can safely treat oral chronic graft-versus-host disease (GVHD), a painful mouth condition that can occur after a stem cell transplant. About 44 participants who have not responded to at least on…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can a smartphone app boost sexual health after a stem cell transplant?
Symptom relief Recruiting nowThis study is testing a new digital application called SHIFT to see if it can improve sexual health, quality of life, and reduce distress in people who have had a stem cell or bone marrow transplant. The trial will enroll 300 adult survivors who are at least three months post-tra…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Exercise may tame steroid side effects in stem cell transplant patients
Symptom relief Recruiting nowThis study looks at whether a home-based aerobic and resistance exercise program is feasible for adults with graft-versus-host disease (GVHD) after a stem cell transplant. Participants will either do aerobic and resistance exercises or simple stretching. The goal is to see if exe…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a virtual support program ease the burden of chronic GVHD?
Symptom relief Recruiting nowThis study tests a group-based telehealth program called HORIZONS for adults living with chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The program includes 8 sessions led by a therapist to help with self-management and quality of life. Researchers will c…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New eye drop offers hope for dry eye in transplant patients
Symptom relief Recruiting nowThis study tests an experimental eye drop (rhPRG4) to see if it safely eases dry eye symptoms in people with ocular graft-versus-host disease (oGVHD), a complication after bone marrow transplant. About 15 adults with moderate to severe dry eye will receive both the active drop an…
Phase: PHASE2 • Sponsor: Lubris Bio Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could a tiny zap to the face soothe chronic eye pain?
Symptom relief Recruiting nowThis pilot study tests whether a non-invasive electrostimulation device can relieve symptoms of chronic ocular graft-versus-host disease, a painful eye condition that can occur after a stem cell transplant. Fifteen participants will receive either real or sham stimulation on thei…
Phase: NA • Sponsor: Zhonghui K. Luo, MD, PhD • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Can online exercise help kids recover after a stem cell transplant?
Symptom relief Recruiting nowThis study tests whether a virtual exercise program can help children and young adults (ages 8-23) recover physical function and quality of life after a stem cell transplant. Participants will have twice-weekly, 30-minute online sessions with a physical therapist for 12 weeks. Th…
Phase: NA • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 26, 2026 18:53 UTC
-
Massive study aims to unravel mysteries of blood clots and vessel disease
Knowledge-focused Recruiting nowThis study aims to learn more about how diseases related to blood clots, the immune system, and blood vessels start and change over time. Researchers will enroll up to 1,000 people aged 5 and older, including those with these conditions, their healthy relatives, and healthy volun…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
Researchers launch major study to unravel mysteries of chronic GVHD
Knowledge-focused Recruiting nowThis study follows 650 people with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. Researchers aim to track the disease over time, identify biological markers, and improve how it is diagnosed and managed. Participants undergo regular check-u…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 03, 2026 23:00 UTC
-
New study aims to spot lung trouble before it starts in transplant patients
Knowledge-focused Recruiting nowThis study looks for better ways to detect lung inflammation and infections early in people who have received a stem cell transplant from a donor. About 40 participants aged 5 to 70 will get regular lung scans, breathing tests, blood draws, and a procedure where a tube collects f…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New PET scan agent may spot hidden GVHD in joints
Knowledge-focused Recruiting nowThis pilot study is testing a new imaging agent called [18F]4FN in PET/CT scans for people with chronic graft-versus-host disease (GVHD) affecting their joints. The goal is to see if the agent is safe and can help doctors see joint problems more clearly. Sixteen adults with chron…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Can a blood test predict which cGVHD treatment works best?
Knowledge-focused Recruiting nowThis study enrolls 300 adults with chronic graft-versus-host disease (cGVHD) who are about to start a new therapy. Researchers will collect blood samples and medical data before and after treatment to look for changes that might predict how well a patient responds. The goal is to…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New MRI technique could spot lung trouble early in transplant patients
Knowledge-focused Recruiting nowThis study is testing a new type of MRI that uses xenon gas to see how well the lungs are working in people who have had a bone marrow transplant. Researchers will scan 25 transplant patients with or without lung problems, plus 10 healthy volunteers. The goal is to see if this MR…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Can a simple questionnaire predict who will follow their treatment?
Knowledge-focused Recruiting nowThis study is testing a tool called B-COMPASS that uses a 22-question survey to predict whether people will follow their prescribed treatments. Researchers will enroll 3100 adults with cardiovascular, endocrine, immune, nerve, cancer, or rare diseases across Europe. The goal is t…
Phase: NA • Sponsor: Technical University of Madrid • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New study tracks 1,500 transplant patients to unlock secrets of a devastating complication
Knowledge-focused Recruiting nowThis study follows 1,500 adults who recently had a stem cell transplant and are at risk for chronic Graft-Versus-Host Disease (cGVHD), a condition where donor cells attack the recipient's body. Researchers will collect data on how often cGVHD occurs, how severe it is, and what he…
Sponsor: Incyte Corporation • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New study seeks answers for Women's Post-Transplant health problems
Knowledge-focused Recruiting nowThis study will follow 100 women who have had a stem cell transplant to better understand a condition called vulvovaginal chronic graft-versus-host disease (cGVHD). Researchers want to learn how common it is, what symptoms look like, and how it affects sexual health. The goal is …
Sponsor: Ciusss de L'Est de l'Île de Montréal • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Massive new registry aims to unlock secrets of biologic drugs
Knowledge-focused Recruiting nowThis study is creating a large registry of 800 people receiving biologic medications for immune conditions like autoimmune diseases and primary immune deficiencies. Researchers will collect blood samples and health data to better understand how these treatments work and who respo…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Nerve check may predict transplant complication risk
Knowledge-focused Recruiting nowThis study looks at 60 people getting a stem cell transplant to see if their autonomic nervous system (which controls things like heart rate and sweating) can help predict a serious complication called graft-versus-host disease (GvHD). Participants will have simple nerve tests be…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Depression may worsen GvHD symptoms, new study investigates
Knowledge-focused Recruiting nowThis study looks at how depression and other mental health issues impact symptom severity and quality of life in people with graft-versus-host disease (GvHD). Researchers will follow 200 adults with GvHD, using questionnaires to measure psychiatric status and symptoms. The goal i…
Sponsor: Medical University of Gdansk • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Why Won't dry eye heal? scientists check nerve damage in GVHD patients
Knowledge-focused Recruiting nowThis study explores whether nerve damage in the cornea causes stubborn dry eye in people with ocular graft-versus-host disease (GVHD), a complication of stem cell transplants. Researchers will measure corneal sensation in 30 GVHD patients and compare it to healthy controls. The g…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
New scan technique could spot lung trouble early in transplant patients
Knowledge-focused Recruiting nowThis study looks at whether a special CT scan analysis called parametric response mapping (PRM) can detect early signs of chronic lung disease in people who have had a stem cell transplant. Researchers will follow 375 patients for one year to see if PRM patterns predict lung func…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC